Description of treatments followed by those subjects with temporary DMA and those with persistent DMA (in the three studies).
| Temporary PDA | Persistent PDA | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| ECRHS1 | ECRHS2 | ECRHS3 | ECRHS1 | ECRHS2 | ECRHS3 | ||||
| n=94 | n=143 | n=182 | n=73 | n=73 | n=73 | ||||
| n (%) | n (%) | n (%) | n (%) | n (%) | n (%) | ||||
| Without treatment | 30 (31.9%) | 51 (35.7%) | 75 (41.2%) | 20 (27.4%) | 22 (30.1%) | 26 (35.6%) | |||
| Recommended treatment | |||||||||
| 1) Inhaled Beta 2 adren | 21 (22.3%) | 30 (21.0%) | 27 (14.8%) | 19 (26.0%) | 17 (23.3%) | 9 (12.3%)§ | |||
| 2) Inh Corticosteroids | 13 (13.8%) | 38 (26.7%) | 70 (38.5%)§ | 12 (16.4%) | 19 (26.0%) | 34 (46.6%)§ | |||
| 3) Oral Corticosteroids | 11 (11.7%) | 15 (10.5%) | 2 (1.1%)§ | 10 (13.7%) | 11 (15.1%) | 1 (1.4%)§ | |||
| No recommended treatment | 19 (20.2%) | 9 (6.3%) | 8 (4.4%)§ | 12 (16.4%) | 4 (5.5%) | 3 (4.1%)§ | |||
[§]: Significant variation between studies I and II with a positive tendency over the course of the three studies.